Barclays
TARA icon

Barclays’s Protara Therapeutics TARA Stock Holding History

Barclays’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Sell
48,262
-6,795
-12% -$40.2K ﹤0.01% 3559
2025
Q4 		$293K Buy
55,057
+9,537
+21% +$53K ﹤0.01% 4140
2025
Q3 		$198K Sell
45,520
-10,119
-18% -$32.8K ﹤0.01% 4321
2025
Q2 		$169K Sell
55,639
-37,600
-40% -$130K ﹤0.01% 4377
2025
Q1 		$397K Hold
93,239
– – ﹤0.01% 3664
2024
Q4 		$492K Buy
+93,239
New +$301K ﹤0.01% 3832
2022
Q2 		– Sell
-2,510
Closed -$13K – 5260
2022
Q1 		$13K Buy
+2,510
New +$13.2K ﹤0.01% 4552
2015
Q4 		– Sell
-1
Closed -$1K – 6545
2015
Q3 		$1K Sell
1
-3
-75% -$1.86K ﹤0.01% 6599
2015
Q2 		$2K Buy
+4
New +$2.47K ﹤0.01% 6819

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Barclays's TARA Position: Q1 2026 in Review

Barclays reduced its Protara Therapeutics (TARA) stake by 12% in Q1 2026, selling an estimated $40.2K and leaving 48,262 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #3559.

Barclays first reported a position in TARA in Q2 2015 and has held it in 9 quarters since. The position peaked at $492K in Q4 2024. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Barclays held 48,262 shares of Protara Therapeutics worth $251K as of Q1 2026.
  • Barclays sold 6,795 Protara Therapeutics shares in Q1 2026, an estimated $40.2K.
  • Protara Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3559 holding.
  • Barclays first reported a position in Protara Therapeutics in Q2 2015 and has held it in 9 quarters since.
  • Barclays's Protara Therapeutics position peaked at $492K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.